Last reviewed · How we verify

NCT07378150

Clay Therapy in Schizophrenia Patients

Recruiting now NA Last updated 30 January 2026
What this trial tests

NA trial testing Clay therapy in Schizophrenia and Related Disorders in 17 participants. Currently enrolling.

Timeline
1 December 2025
Primary endpoint
9 January 2026
20 February 2026

Quick facts

Lead sponsorKutahya Health Sciences University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment17
Start date1 December 2025
Primary completion9 January 2026
Estimated completion20 February 2026
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Kutahya Health Sciences University

Who can join

18 and older, any sex, with Schizophrenia and Related Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In recent years, art therapies have been discussed for their positive effects on mental disorders. One such therapy, clay therapy, is being studied to examine its effect on the functional recovery and individual and social performance of schizophrenia patients undergoing pharmacological treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Schizophrenia and Related Disorders

Currently open trials in the same condition.

Other Kutahya Health Sciences University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07378150.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing